Effects of adrenal medulla graft on recovery of GABAergic and dopaminergic neuron deficits in mice: behavioural, pharmacological and immunohistochemical study.
We studied the capacity of adrenal medullary transplant to restore the deficits of GABAergic and dopaminergic neurons in mice injected with quinolinic acid (QA), using an open field test as well as pharmacological and immunohistochemical techniques. We analysed behavioural traits-total locomotor activity, peripheral and central activities, grooming, leaning and rearing in the QA-lesioned mice and mice that had undergone adrenal medulla (AM) transplantation. We found that the adrenal transplant recovered a loss of GABAergic neurons. It reduced QA-induced hyperactivity in locomotion and improved emotional indices. In addition, immunohistochemical studies of catecholaminergic markers-tyrosine hydroxylase (TH), dopamine (DA) and neuronal vesicular monoamine transporter type 2- and a single post-trial injection of tetrabenazine (TBZ; 5 mg/kg) indicated that catecholamines-synthesising chromaffin cells in the AM grafts were also involved in the beneficial effects. A likely interpretation of this behavioural pattern of results is that adrenal medullary transplants set into play an interaction between GABAergic and DAergic factors. Our results may contribute to the clarification of the beneficial effects of AM transplants in striatal function.
Jousselin-Hosaja
M
M
Laboratoire de Neurobiologie des Signaux Intercellulaires, Université Pierre et Marie Curie, CNRS, URM 7101, 7 Quai Saint Bernard, 75252 Paris, Cedex 05, France. maria.jousselin-hosafa@snv.jussieu.fr
Tobin
C
C
Venault
P
P
Joubert
C
C
Chapouthier
G
G
D000313:Adrenal Medulla / Q000502:physiology / Q000637:transplantation*; D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000293:injuries / Q000473:pathology; D004298:Dopamine / Q000378:metabolism*; D007150:Immunohistochemistry; D008124:Locomotion / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism; D026901:Membrane Transport Proteins; D051379:Mice; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000378:metabolism / Q000502:physiology / Q000637:transplantation*; D009479:Neuropeptides; D009498:Neurotoxins / Q000633:toxicity; D017378:Quinolinic Acid / Q000633:toxicity; D013747:Tetrabenazine / Q000494:pharmacology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D050492:Vesicular Biogenic Amine Transport Proteins; D050493:Vesicular Monoamine Transport Proteins; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D018759:Adrenergic Uptake Inhibitors; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009479:Neuropeptides; D009498:Neurotoxins; D050492:Vesicular Biogenic Amine Transport Proteins; D050493:Vesicular Monoamine Transport Proteins; D005680:gamma-Aminobutyric Acid; D014446:Tyrosine 3-Monooxygenase; D017378:Quinolinic Acid; D004298:Dopamine; D013747:Tetrabenazine